Abstract 38P
Background
We aimed to investigate the efficacy of locoregional radiotherapy (LRRT) in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving chemotherapy combined with anti-programmed cell death receptor-1 monoclonal antibodies (anti-PD-1 mAbs) as first-line treatment and to identify optimal LRRT candidates based on Epstein-Barr Virus DNA (EBV DNA).
Methods
We enrolled patients with dmNPC receiving platinum-based palliative chemotherapy and anti-PD-1 mAbs followed or not followed by LRRT from four centers. The endpoints were progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Additionally, we used the inverse probability of treatment weighting (IPTW) to balance baseline characteristics of the LRRT and no-LRRT groups to minimize selection bias before the comparative analyses. Multivariate analyses were performed using the Cox proportional hazards model.
Results
We included 163 patients with dmNPC (median follow-up: 22 months). The median PFS was 20 months, and the ORR was 69.2%; the median OS was not achieved. After the IPTW adjustments, patients who received LRRT had a significant survival benefit over those who did not receive LRRT (median PFS: 28 months vs. 14 months; ORR: 81.0% vs. 48.3%; all P <0.001). The EBV DNA level after four to six cycles of anti-PD-1 mAbs (weighted hazard ratio [HR]: 2.01, 95% confidence interval [CI]: 1.11−3.65, P = 0.02) and LRRT (weighted HR: 0.58, 95% CI: 0.34−0.99, P = 0.04) were independent prognostic factors. Patients with undetectable EBV DNA levels after four to six cycles of anti-PD-1 mAbs (early EBV DNA clearance) benefitted from LRRT (HR: 0.43, 95% CI: 0.23−0.80, P = 0.007), whereas patients with detectable levels did not (HR: 1.03, 95% CI: 0.47−2.26, P = 0.93).
Conclusions
Palliative chemotherapy combined with anti-PD-1 mAbs followed by LRRT was associated with improved survival outcomes in patients with dmNPC, especially for patients with early EBV DNA clearance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
Presenter: Abhishek Krishna
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions
Presenter: Randa Mahran
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
Presenter: Nancy Loos
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from <italic>Daucus carota</italic> as a potential therapy for triple-negative breast cancer
Presenter: Kayode Raheem
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
Presenter: Corinne Vannier
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
Presenter: Heloise Beutier
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
Presenter: Sofija Jovanović Stojanov
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
Presenter: Edoardo Crimini
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - MDM alterations in patients with advanced or metastatic cancers
Presenter: Iwona Lugowska
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Automated detection of typical and atypical mitotic figures for improving survival prediction in breast cancer
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract